KRN7000 applied to lung cancer research

Allogeneic DCG promote lung NK cell activation and antitumor effect after invariant NKT cell activation

Tuberous Sclerosis 1 Promotes Invariant NKT Cell Anergy and Inhibits Invariant NKT Cell-Mediated Antitumor Immunity

Combining Carbon Ion Radiotherapy and Local Injection of α-Galactosylceramide-Pulsed Dendritic Cells Inhibits Lung Metastases in an In Vivo Murine Model

A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy

Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation

A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer

Interleukin-2 gene transfer potentiates the alpha-galactosylceramide-stimulated antitumor effect by the induction of TRAIL in NKT and NK cells in mouse models of subcutaneous and metastatic carcinoma

A Phase I Study of Alpha-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer

Activation of Valpha24NKT cells in malignant pleural effusion in patients with lung cancer

Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases

Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18

Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells

Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients

A Phase I Study of In vitro Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer

Cutting Edge: Inhibition of Experimental Tumor Metastasis by Dendritic Cells Pulsed with alpha-Galactosylceramide

Natural Killer T Cell–Based Cancer Immunotherapy

Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer

KRN7000 in Treating Patients With Solid Tumors- lung cancer

Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide

Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells

Back to top

New 7DW8-5 glycolipid

7DW8-5

Now available 7DW8-5 glycolipid derivative of Alpha-GalCer for human and mice iNKT immunoresearch

 

Meet Funakoshi Company
at the following meetings:

NIH Festival
Bethesda, Maryland
September 14-15, 2017

The 76th Annual Meeting of the Japanese Cancer Association
Yokohama, Japan
September 28-30, 2017

ASCB
Philadelphia, PA
December 2-6, 2017